TDD in dermatology aims to prolong, localize, and target drug interactions with the diseased skin, leading to improved treatment outcomes and quality of the patients life [181]
There are several GLP-1 medications on the market, and new ones including an upcoming oral pill called orforglipron are in the pipeline
This concentration is more likely to deliver results in a shorter period of time compared to the 0.025% strength
In August 2025, the FDA also approved Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis 8
GLP-1 receptor agonists as a class share similar mechanisms and therefore comparable digestive effects, though individual medications show some distinctions
Whilst not listed as a specific adverse effect in the Summary of Product Characteristics, belching and gastrointestinal disturbances are common with Rybelsus, particularly during initial treatment